Enzon Pharmaceuticals, Inc. (ENZN)
OTCMKTS: ENZN · Delayed Price · USD
0.170
0.00 (0.00%)
Jul 3, 2024, 9:30 AM EDT - Market closed
Company Description
Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations.
Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.
The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002.
Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.
Enzon Pharmaceuticals, Inc.
| Country | United States |
| Founded | 1981 |
| IPO Date | Feb 15, 1984 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Richard L. Feinstein CPA |
Contact Details
Address: 20 Commerce Drive, Suite 135 Cranford, New Jersey 07016 United States | |
| Phone | 732-980-4500 |
| Website | enzon.com |
Stock Details
| Ticker Symbol | ENZN |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000727510 |
| CUSIP Number | 293904108 |
| ISIN Number | US2939041081 |
| Employer ID | 22-2372868 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Richard L. Feinstein | Chief Executive Officer, Chief Financial Officer and Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2024 | 8-K | Current Report |
| Jun 14, 2024 | 8-K | Current Report |
| May 22, 2024 | 8-A12G/A | Filing |
| May 22, 2024 | 8-K | Current Report |
| May 10, 2024 | 10-Q | Quarterly Report |
| Apr 26, 2024 | 10-K/A | [Amend] Annual report |
| Mar 20, 2024 | 10-K | Annual Report |
| Jan 5, 2024 | 8-K | Current Report |
| Nov 9, 2023 | 10-Q | Quarterly Report |
| Aug 7, 2023 | 10-Q | Quarterly Report |